Chimeric antigen receptor (CAR) T-cell therapies have shown considerably high response rates even in RR-LBCL patients who fail to achieve remission after multiple chemotherapy lines. Currently, three CAR T-cell treatments axicabtagene ciloleucel (Yescarta), tisagenlecleucel (Kymriah), and liso...
a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy
The new challenge has become how cell therapies will be paid for. There are also JW Therapeutics and other more than 20 CD19-directed CAR-T being developed in China. In addition, Legend’s BCMA-directed CAR-T therapy for myeloma is expected to be launched in America this year. The cost...
Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (...
Is the NHS ready for CAR T therapies? "In many ways, this treatment is more akin to a stem cell transplant than traditional chemotherapy," says Peggs. NHS England has selected hospitals where staff have experience of procedures like stem cell or bone marrow transplants as the first locations...
CAR T-cell therapy was initially approved by the FDA for patients who had relapsed/refractory large B-cell lymphomas, according to Neelapu. However, these therapies have since been investigated in early lines of therapy, as is being done in the phase 2 ZUMA-12 study (NCT03761056), as well...
Expanding Access to Chimeric Antigen Receptor T-Cell Therapies: Challenges and Opportunities Chimeric antigen receptor (CAR) T銉絜ll therapy is a major advancement in the treatment of lymphoid malignancies, especially diffuse large B銉絜ll lymphoma and acute lymphoblastic leukemia (ALL). Since the U...
CAR T-Cell Therapy in Myeloma Tools to Monitor for ICANS During Lymphoma Treatment With Bispecific Antibodies, CAR T-Cell Therapy ‘Bringing Every Single Resource’ When Caring for Patients Receiving Treatment for Gynecologic Cancers Starting CML Treatment: Collaborative Choices for ...
The CAR-T cell therapy was approved to treat patients with relapsed or refractory multiple myeloma after receiving 4 or more lines of prior therapy, including the three classes of main treatments. This approval was based on findings from the phase 3 KarMMa-3 trial (NCT03651128). In this ...
Approved car T cell therapies: Ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov. Today 2018, 23, 1175–1182. [CrossRef] 32. Zuñiga, L.; Calvo Hernáez, M.B. Biosimilars—The way forward. Hosp. Pharm. Eur. 2010, 50, 1–2. 33. Siramshetty, V.B....